

EU SUMMARY TABLE

DS19-01: The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.

General Data Protection Regulation (GDPR) limits the release of European Union patient-level data publicly.

Characteristic	N (%)
No. of patients	49
Cryopreservation - no. (%)	
Fresh	43 (88)
Cryopreserved	6 (12)
Recipient age - median (min-max)	53 (12-72)
Recipient sex - no. (%)	
Male	23 (47)
Female	26 (53)
Performance score - no. (%)	
90-100	40 (82)
<90	5 (10)
Missing	4 (8)
HCT-CI - no. (%)	
0	29 (59)
1 – 2	11 (22)
3+	9 (18)
Primary disease - no. (%)	
AML	26 (53)
ALL	5 (10)
CML	1 (2)
MDS/MPN	9 (18)
Other acute leukemia	1 (2)
NHL	4 (8)
HL	3 (6)
Conditioning regimen intensity - no. (%)	
MAC	14 (29)
RIC/NMA	35 (71)
TBI - no. (%)	
No	25 (51)
Yes	24 (49)
ATG/alemtuzumab - no. (%)	
ATG alone	18 (37)
Alemtuzumab alone	7 (14)
No ATG or alemtuzumab	24 (49)
GVHD prophylaxis - no. (%)	
TAC + MMF +- other(s) (except post-CY)	12 (24)
CSA + MMF +- other(s) (except post-CY)	5 (10)
CSA + MTX +- other(s) (except MMF, post-CY)	25 (51)
CSA alone	7 (14)

Characteristic	N (%)
Graft type - no. (%)	
Bone marrow	5 (10)
Peripheral blood	44 (90)
Donor group - no. (%)	
HLA-identical sibling	19 (39)
Unrelated, 8/8	25 (51)
Unrelated, 7/8	5 (10)
Year of transplant - no. (%)	
2013	10 (20)
2014	13 (27)
2015	6 (12)
2016	8 (16)
2017	4 (8)
2018	8 (16)